Alzheimer’s Diagnostics Moves to the Living Room
Three-minute tablet test, painless blood collection at home, 500,000 metabolic profiles: This week, Alzheimer’s diagnostics is moving from the specialist clinic to the living room. As doctors look ahead to the upcoming CTAD conference in San Diego, biotech companies and research institutes have already created facts between November 18th and 21st.
Linus Health showed on Tuesday how AI turns a 3-minute test into an accurate screening tool. Neurogen and Tasso announced on Thursday a partnership that brings clinically precise blood tests to the home. Published almost simultaneously occurring UK Biobank the world’s largest data set on chemical dementia signatures in the blood – years before the first symptoms appear.
The Boston company Linus health has digitized the classic watch test. On November 18th, the company published preliminary data for Digital Clock and Recall (DCR) tests that will be presented in detail at the CTAD conference in early December.
The innovation: A tablet records not onyl the end result of the drawn clock, but the entire process. Hesitation, pressure intensity, speed – the AI analyzes every stroke. The result: The test predicts with high accuracy whether Amyloid deposits are present in the brain, the main pathological feature of Alzheimer’s.
Advertisement
In keeping with the topic of early detection – if you are worried about forgetfulness, a short, anonymous 7-question self-test can provide initial information in around 2 minutes. The test was developed with experts, gives an understandable assessment and helps decide whether further blood or imaging tests make sense. It offers quick orientation, especially for relatives, before complex examinations become necessary.Free and anonymous. Start the anonymous 2-minute dementia self-test now
A parallel study demonstrated that the Digital Assessment of Cognition (DAC) can even predict the status of the blood biomarker p-tau217. In the future, family doctors could use a simple tablet screening to decide which patient needs expensive follow-up examinations.
Blood collection without a needle and a visit to the doctor
two days later, on November 20, Neurogen Biomarking and Tasso Inc.announced a strategic partnership. it eliminates the biggest bottleneck in Alzheimer’s diagnosis: the visit to the doctor to have a blood sample taken.
Until now,high-precision tests for Alzheimer’s biomarkers such as p-tau217 required venous blood sampling by specialist personnel. The new collaboration integrates Tasso+ technology into Neurogen’s testing ecosystem.